Literature DB >> 33536023

Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole.

L D Crosby1, S Kalanidhi1, A Bonilla1,2, A Subramanian1, J S Ballon1, H Bonilla3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33536023      PMCID： PMC7860172          DOI： 10.1186/s12967-021-02721-9

Source DB:  PubMed          Journal:  J Transl Med        ISSN： 1479-5876            Impact factor:   5.531


× No keyword cloud information.
  6 in total

Review 1.  Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness.

Authors: 
Journal:  Mil Med       Date:  2015-07       Impact factor: 1.437

2.  Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.

Authors:  Katerina Horska; Jana Ruda-Kucerova; Eva Drazanova; Michal Karpisek; Regina Demlova; Tomas Kasparek; Hana Kotolova
Journal:  Neuropharmacology       Date:  2017-09-01       Impact factor: 5.250

3.  Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome.

Authors:  Yiqing Yan; Wei Jiang; Lei Liu; Xiaqiong Wang; Chen Ding; Zhigang Tian; Rongbin Zhou
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

4.  Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity.

Authors:  Jarosław Sobiś; Monika Rykaczewska-Czerwińska; Elżbieta Świętochowska; Piotr Gorczyca
Journal:  Pharmacol Rep       Date:  2014-09-26       Impact factor: 3.024

5.  Cytokine signature associated with disease severity in chronic fatigue syndrome patients.

Authors:  Jose G Montoya; Tyson H Holmes; Jill N Anderson; Holden T Maecker; Yael Rosenberg-Hasson; Ian J Valencia; Lily Chu; Jarred W Younger; Cristina M Tato; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-31       Impact factor: 11.205

6.  Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study.

Authors:  Yasuhito Nakatomi; Kei Mizuno; Akira Ishii; Yasuhiro Wada; Masaaki Tanaka; Shusaku Tazawa; Kayo Onoe; Sanae Fukuda; Joji Kawabe; Kazuhiro Takahashi; Yosky Kataoka; Susumu Shiomi; Kouzi Yamaguti; Masaaki Inaba; Hirohiko Kuratsune; Yasuyoshi Watanabe
Journal:  J Nucl Med       Date:  2014-03-24       Impact factor: 10.057
  6 in total
  6 in total

1.  Publisher Correction to: Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole.

Authors: 
Journal:  J Transl Med       Date:  2021-05-21       Impact factor: 5.531

2.  The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure.

Authors:  Herbert Renz-Polster; Marie-Eve Tremblay; Dorothee Bienzle; Joachim E Fischer
Journal:  Front Cell Neurosci       Date:  2022-05-09       Impact factor: 6.147

Review 3.  [Post-COVID syndrome-Focus fatigue].

Authors:  Sabine Hellwig; Katharina Domschke
Journal:  Nervenarzt       Date:  2022-05-23       Impact factor: 1.297

4.  Treatments of chronic fatigue syndrome and its debilitating comorbidities: a 12-year population-based study.

Authors:  Kam-Hang Leong; Hei-Tung Yip; Chien-Feng Kuo; Shin-Yi Tsai
Journal:  J Transl Med       Date:  2022-06-11       Impact factor: 8.440

5.  Extremely Severe ME/CFS-A Personal Account.

Authors:  Whitney Dafoe
Journal:  Healthcare (Basel)       Date:  2021-04-27

Review 6.  Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review.

Authors:  Stanley Du Preez; Helene Cabanas; Donald Staines; Sonya Marshall-Gradisnik
Journal:  Int J Environ Res Public Health       Date:  2021-10-12       Impact factor: 3.390
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.